icer value assessment framework

icer value assessment framework is a critical tool used in healthcare decision-making to evaluate the cost-effectiveness and overall value of medical interventions. This framework helps policymakers, payers, and healthcare providers make informed choices by comparing the incremental cost of a treatment to its incremental health benefits, typically measured in quality-adjusted life years (QALYs). Understanding the principles and applications of the ICER value assessment framework is essential for optimizing resource allocation and improving patient outcomes in a cost-constrained environment. This article explores the foundation of the ICER framework, its methodology, benefits, challenges, and its evolving role in health economics and outcomes research. Additionally, the article provides insight into how the ICER framework influences pricing, reimbursement decisions, and the broader landscape of healthcare value assessment.

- Understanding the ICER Value Assessment Framework
- Key Components of the ICER Framework
- Methodology and Calculation of ICER
- Applications of the ICER Framework in Healthcare
- Advantages and Limitations of the ICER Framework
- Future Trends in Value Assessment Using ICER

Understanding the ICER Value Assessment Framework

The ICER value assessment framework is designed to measure the value of healthcare interventions by analyzing their costs relative to their health outcomes. ICER stands for Incremental Cost-Effectiveness Ratio, which quantifies the additional cost associated with one additional unit of health benefit, such as a quality-adjusted life year (QALY). This framework is widely used by health technology assessment (HTA) bodies, insurers, and government agencies to guide coverage and pricing decisions. By providing a systematic approach to value assessment, the ICER framework supports evidence-based decision-making in healthcare.

Historical Background and Development

The concept of cost-effectiveness analysis in healthcare dates back several decades, but the formal ICER

framework gained prominence as a standardized method to evaluate new medical technologies and pharmaceuticals. Initially developed to address rising healthcare costs and variability in treatment effectiveness, the ICER framework has evolved to incorporate broader value elements including patient preferences, societal impacts, and long-term outcomes.

Purpose and Impact

The primary purpose of the ICER value assessment framework is to optimize healthcare resource allocation by identifying interventions that provide the most significant health benefits at acceptable costs. This approach helps to minimize wasteful spending while ensuring that patients have access to clinically effective and economically viable treatments. The framework's impact extends to influencing drug pricing negotiations, insurance reimbursement policies, and clinical guideline development.

Key Components of the ICER Framework

The ICER value assessment framework comprises several critical components that work together to determine the value of a healthcare intervention. Each component provides insight into different aspects of the intervention's economic and clinical profile.

Incremental Costs

This component captures the difference in costs between the new intervention and the comparator, which could be an existing treatment or standard of care. Costs include direct medical expenses such as drug acquisition, administration, monitoring, and adverse event management. Indirect costs, such as productivity losses, may also be considered depending on the perspective taken.

Incremental Effectiveness

Incremental effectiveness refers to the additional health benefits gained from the intervention compared to the comparator. Typically measured in QALYs, this component reflects both the quantity and quality of life years added by the treatment.

Cost-Effectiveness Thresholds

The ICER framework uses predefined cost-effectiveness thresholds to interpret whether an intervention provides good value for money. These thresholds vary by country and healthcare system but generally represent the maximum amount a payer is willing to spend per additional QALY gained.

Other Value Elements

Modern ICER assessments may incorporate supplementary factors such as disease severity, unmet medical need, innovation level, and societal impact to provide a comprehensive evaluation of value beyond cost and effectiveness alone.

Methodology and Calculation of ICER

The calculation of the Incremental Cost-Effectiveness Ratio is a systematic process that involves gathering data on costs and outcomes, followed by rigorous analysis to produce a meaningful ratio.

Data Collection and Sources

Data for ICER calculations are sourced from clinical trials, observational studies, real-world evidence, and economic models. Accurate and comprehensive data collection is essential to ensure the reliability of the assessment.

Calculating the Incremental Cost-Effectiveness Ratio

The basic formula for ICER is:

1. Calculate the difference in costs between the new intervention and the comparator (Incremental Cost).

2. Calculate the difference in effectiveness between the intervention and comparator (Incremental Effectiveness, usually in QALYs).

3. Divide the incremental cost by the incremental effectiveness:

ICER = (Cost of Intervention – Cost of Comparator) / (Effectiveness of Intervention – Effectiveness of Comparator)

Interpreting ICER Results

Once calculated, the ICER is compared against established cost-effectiveness thresholds. An ICER below the threshold suggests the intervention is cost-effective, whereas a value above may indicate it is not an economically favorable option. Decision-makers use these results to guide reimbursement and funding choices.

Applications of the ICER Framework in Healthcare

The ICER value assessment framework plays a vital role in multiple areas of healthcare decision-making, influencing both policy and practice.

Health Technology Assessment (HTA)

HTA agencies use the ICER framework to evaluate new pharmaceuticals, medical devices, and treatment protocols. These assessments inform recommendations for inclusion in formularies and coverage by public and private payers.

Payer Decision-Making

Insurance companies and government payers rely on ICER evaluations to determine reimbursement levels and negotiate pricing agreements with manufacturers. ICER outcomes help balance affordability with patient access to innovative therapies.

Clinical Guidelines and Practice

Professional medical societies incorporate ICER findings into clinical guidelines to promote the use of cost-effective treatments. This alignment ensures that clinical practice supports both quality care and economic sustainability.

Pharmaceutical Pricing and Market Access

The ICER framework influences pharmaceutical companies' pricing strategies and market access planning. Demonstrating cost-effectiveness through ICER assessments can facilitate faster adoption and reimbursement approval.

Advantages and Limitations of the ICER Framework

While the ICER value assessment framework offers significant benefits, it also has inherent limitations that must be considered in its application.

Advantages

- **Objective Evaluation:** Provides a quantitative and standardized measure of value.
- **Resource Optimization:** Supports efficient allocation of limited healthcare resources.
- **Transparency:** Enhances transparency in decision-making processes.
- **Encourages Innovation:** Incentivizes development of treatments that improve health outcomes cost-effectively.

Limitations

- **Data Limitations:** Quality and availability of data can affect accuracy.
- **Threshold Variability:** Cost-effectiveness thresholds differ by region, impacting consistency.
- **Non-Quantifiable Factors:** Difficulties in incorporating qualitative factors like patient preferences and ethical considerations.
- **Potential Oversimplification:** May not capture the full complexity of healthcare value.

Future Trends in Value Assessment Using ICER

The ICER value assessment framework is continuously evolving to address the dynamic landscape of healthcare innovation and policy.

Integration of Real-World Evidence

Increasingly, real-world data is being incorporated into ICER analyses to complement clinical trial results and provide more generalizable insights into treatment effectiveness and safety.

Broader Value Frameworks

Future assessments aim to expand beyond traditional cost-effectiveness by including elements such as equity, caregiver burden, and societal benefits to better capture comprehensive value.

Personalized Medicine and ICER

As precision medicine advances, the ICER framework is adapting to evaluate personalized therapies that may have higher upfront costs but deliver targeted benefits for specific patient populations.

Global Harmonization Efforts

Efforts are underway to harmonize cost-effectiveness thresholds and methodologies internationally to improve comparability and facilitate global healthcare decision-making.

Frequently Asked Questions

What is the ICER value assessment framework?

The ICER value assessment framework is a methodology developed by the Institute for Clinical and Economic Review to evaluate the clinical and economic value of healthcare interventions, such as drugs and medical devices.

How does ICER determine the value of a healthcare treatment?

ICER assesses value by analyzing clinical effectiveness, cost-effectiveness, and the potential budget impact, incorporating health outcomes like quality-adjusted life years (QALYs) and comparing costs to benefits.

Why is the ICER value assessment framework important for healthcare decision-making?

It provides a standardized, transparent approach to evaluate the value of treatments, helping payers, policymakers, and providers make informed decisions about resource allocation and coverage.

What types of interventions are evaluated using the ICER framework?

The framework is used to assess a wide range of interventions, including pharmaceuticals, medical devices, and other health technologies.

How does ICER incorporate patient perspectives in its value assessments?

ICER includes patient and caregiver input through public comment periods, advisory panels, and by considering patient-reported outcomes and quality-of-life measures in its evaluations.

What role do cost-effectiveness thresholds play in the ICER value assessment framework?

ICER uses cost-effectiveness thresholds, often expressed as cost per QALY gained, to determine whether an intervention provides good value for money compared to existing treatments.

How can pharmaceutical companies use the ICER value assessment framework?

Companies can use ICER's framework to understand value expectations, guide pricing strategies, and prepare evidence submissions that demonstrate the clinical and economic benefits of their products.

What are some criticisms of the ICER value assessment framework?

Criticisms include concerns about over-reliance on QALYs, potential biases in value judgments, and the framework not fully capturing all aspects of patient benefit or innovation.

How is the ICER value assessment framework evolving with emerging healthcare trends?

ICER is continuously updating its framework to incorporate new data sources, address rare diseases, include equity considerations, and adapt to innovations such as gene therapies and personalized medicine.

Additional Resources

1. *Understanding the ICER Value Assessment Framework: A Comprehensive Guide*
This book offers an in-depth exploration of the Institute for Clinical and Economic Review (ICER) value assessment framework, breaking down its methodology and applications. It explains how ICER evaluates the cost-effectiveness of healthcare interventions, balancing clinical benefits with economic considerations. Readers will gain insights into the framework's role in health policy decision-making and drug pricing debates.

2. *Health Economics and the ICER Framework: Principles and Practice*
Focusing on the intersection of health economics and value assessment, this text delves into how the ICER framework incorporates economic evaluation techniques. It covers topics such as quality-adjusted life years (QALYs), budget impact analyses, and cost-effectiveness thresholds. Suitable for students and professionals, it provides practical examples of ICER's application in real-world scenarios.

3. *Pharmacoeconomics and ICER: Evaluating Drug Value in Modern Healthcare*
This book addresses the role of the ICER framework in pharmacoeconomics, specifically in assessing the value of pharmaceuticals. It discusses the challenges of measuring drug benefits and costs, and how ICER's

reports influence payer decisions and market access. The text also critiques the framework's limitations and proposes future directions for value assessment.

4. *Patient-Centered Value Assessment: Innovations within the ICER Framework*
Highlighting the importance of patient perspectives, this book explores how the ICER framework integrates patient-centered outcomes into value assessments. It reviews methodologies for capturing patient preferences, quality of life measures, and equity considerations. The book advocates for more inclusive and transparent assessment practices that reflect diverse stakeholder views.

5. *Comparative Effectiveness Research and ICER: Tools for Informed Healthcare Decisions*
This volume examines the synergy between comparative effectiveness research (CER) and the ICER value framework. It explains how CER data informs ICER's evaluations of clinical benefits and cost-effectiveness. Readers will learn about study designs, data sources, and analytic methods that underpin robust value assessments.

6. *Policy Implications of the ICER Value Assessment Framework*
Focusing on health policy, this book analyzes the impact of ICER's assessments on healthcare regulation, reimbursement, and pricing strategies. It discusses controversies surrounding ICER's influence on drug approval and coverage decisions. The text also explores how policymakers can leverage ICER findings to promote sustainable and equitable healthcare systems.

7. *Advanced Methods in Cost-Effectiveness Analysis: Insights from the ICER Framework*
This technical book is geared toward health economists and analysts interested in advanced methodologies used within the ICER framework. Topics include modeling techniques, sensitivity analyses, and handling uncertainty in cost-effectiveness studies. The book provides practical guidance on conducting rigorous economic evaluations aligned with ICER standards.

8. *Transparency and Accountability in Value Assessment: The Role of ICER*
This book investigates the principles of transparency and accountability in the ICER value assessment process. It critiques the framework's openness in data reporting, stakeholder engagement, and methodological choices. The author suggests improvements to ensure fairness and public trust in value-based healthcare decisions.

9. *Global Perspectives on Value Assessment Frameworks: Learning from ICER*
Offering an international viewpoint, this book compares the ICER framework with other global value assessment models. It highlights similarities and differences in methodologies, cultural contexts, and policy impacts. The text serves as a resource for policymakers and researchers interested in adopting or adapting ICER-inspired approaches worldwide.

Icer Value Assessment Framework

icer value assessment framework: *The ^ARight Price* Peter J. Neumann, Joshua T. Cohen, Daniel A. Ollendorf, 2021-05-06 The Right Price provides an accessible guide to pharmaceutical markets and analytic techniques used to measure the value of drug therapies. It unveils why the pricing of drugs continues to be so challenging and how public and private officials can create more informed policies to achieve the right balance between drug pricing and value.

icer value assessment framework: Healthcare Economics Made Easy, third edition Daniel Jackson, 2021-06-19 Healthcare Economics Made Easy, third edition is a clear and concise text written for those working in healthcare who need to understand the basics of the subject but who do not want to wade through a specialist health economics text. It will equip the reader with the necessary skills to make valid decisions based on the economic data and with the background knowledge to understand the health economics literature. This new edition builds on the success of the second edition by updating the material on the NICE appraisal process and including new sections on health technology assessment in the USA and the key role of the Institute for Clinical and Economic Review. This book provides insight into the economic methods that are used to promote public health policies, the techniques used for grading and valuing evidence and the statistics relied upon, without trying to re-train the reader as a health economist. If you are left bemused by terms such as QALY, health utility analysis and cost-minimization analysis, then this is the book for you! Second edition Highly Commended in the BMA Medical Book Awards! Here’s what the judges said: “This is one of the few textbooks I would suggest every clinician reads.”

icer value assessment framework: Decision Making in a World of Comparative Effectiveness Research Howard G. Birnbaum, Paul E. Greenberg, 2017-05-05 In the past decade there has been a worldwide evolution in evidence-based medicine that focuses on real-world Comparative Effectiveness Research (CER) to compare the effects of one medical treatment versus another in real world settings. While most of this burgeoning literature has focused on research findings, data and methods, Howard Birnbaum and Paul Greenberg (both of Analysis Group) have edited a book that provides a practical guide to decision making using the results of analysis and interpretation of CER. Decision Making in a World of Comparative Effectiveness contains chapters by senior industry executives, key opinion leaders, accomplished researchers, and leading attorneys involved in resolving disputes in the life sciences industry. The book is aimed at 'users' and 'decision makers' involved in the life sciences industry rather than those doing the actual research. This book appeals to those who commission CER within the life sciences industry (pharmaceutical, biologic, and device manufacturers), government (both public and private payers), as well as decision makers of all levels, both in the US and globally.

icer value assessment framework: Real-World Evidence in Drug Development and Evaluation Harry Yang, Binbing Yu, 2021-01-11 Real-world evidence (RWE) has been at the forefront of pharmaceutical innovations. It plays an important role in transforming drug development from a process aimed at meeting regulatory expectations to an operating model that leverages data from disparate sources to aid business, regulatory, and healthcare decision making. Despite its many benefits, there is no single book systematically covering the latest development in the field. Written specifically for pharmaceutical practitioners, Real-World Evidence in Drug Development and Evaluation, presents a wide range of RWE applications throughout the lifecycle of drug product development. With contributions from experienced researchers in the pharmaceutical industry, the book discusses at length RWE opportunities, challenges, and solutions. Features Provides the first book and a single source of information on RWE in drug development Covers a broad array of topics on outcomes- and value-based RWE assessments Demonstrates proper

Bayesian application and causal inference for real-world data (RWD) Presents real-world use cases to illustrate the use of advanced analytics and statistical methods to generate insights Offers a balanced discussion of practical RWE issues at hand and technical solutions suitable for practitioners with limited data science expertise

icer value assessment framework: *Sick to Debt* Peter A. Ubel, 2019-11-26 An informed argument for reworking the broken market†‘based U.S. healthcare system by making cost and quality more transparent The United States has the most expensive healthcare system in the world. While policy makers have argued over who is at fault for this, the system has been quietly moving toward high†‘deductible insurance plans that require patients to pay large amounts out of pocket before insurance kicks in. The idea behind this shift is that patients will become better consumers of healthcare when forced to pay for their medical expenses. Laying bare the perils of the current situation, Peter A. Ubel—a physician and behavioral scientist—notes that even when patients have time to shop around, healthcare costs remain largely opaque, difficult to access, and hard to compare. Arguing for a middle path between a market†‘based and a completely free system, Ubel envisions more transparent, smarter healthcare plans that tie the prices of treatments to the value they provide so that people can afford to receive the care they deserve.

icer value assessment framework: Earthquake: How the Ever-shifting Healthcare Model Victimizes Americans Brian H. Casull MD, MPA, 2019-06-11 Healthcare in America is littered with confusing rules and unclear systems. The discussion is oft centered on misconstrued facts and downright lies. Some politicians claim that nobody ever died from lack of access, that the Affordable Care Act is unnecessary and American healthcare isn’t cost-prohibitive. Some claim no one has lost Medicare or Medicaid coverage and pre-existing conditions don’t threaten coverage. One thing that can’t be denied about American healthcare is how often the average consumer is left confused. “Earthquake: How the Ever-shifting Healthcare Model Victimizes Americans” uses an easy-to-understand metaphor that equates the ever-shifting healthcare system with tectonic plates: just as earthquakes create victims with every shift of tectonic plates, so does the unstable American healthcare system. Dr. Brian Casull, a physician and physician executive of over 40 years, provides information that will help you escape to solid ground, including discussions about: What drives healthcare cost and what you can do about it; What the Affordable Care Act does and doesn’t do; The on-going political assault on your healthcare including pre-existing conditions, preventive care and the 10 essential categories of care you rightfully deserve. “Earthquake” aims to give you, the average healthcare consumer, the information necessary to become informed about America’s healthcare system and understand the tectonic plates that make your healthcare shake and tremble. With this book in hand, you can stay up-to-date on America’s Healthcare in Transition.

icer value assessment framework: The End of Food Allergy Kari Nadeau MD, PhD, Sloan Barnett, 2023-08-29 A life-changing, research-based program that will end food allergies in children and adults forever. The problem of food allergy is exploding around us. But this book offers the first glimpse of hope with a powerful message: You can work with your family and your doctor to eliminate your food allergy forever. The trailblazing research of Dr. Kari Nadeau at Stanford University reveals that food allergy is not a life sentence, because the immune system can be retrained. Food allergies--from mild hives to life-threatening airway constriction--can be disrupted, slowed, and stopped. The key is a strategy called immunotherapy (IT)--the controlled, gradual reintroduction of an allergen into the body. With innovations that include state-of-the-art therapies targeting specific components of the immune system, Dr. Nadeau and her team have increased the speed and effectiveness of this treatment to a matter of months. New York Times bestselling author Sloan Barnett, the mother of two children with food allergies, provides a lay perspective that helps make Dr. Nadeau's research accessible for everyone. Together, they walk readers through every aspect of food allergy, including how to find the right treatment and how to manage the ongoing fear of allergens that haunts so many sufferers, to give us a clear, supportive plan to combat a major national and global health issue.

icer value assessment framework: Drugs, Money, and Secret Handshakes Robin Feldman,

2019-04-11 In the warped world of prescription drug pricing, generic drugs can cost more than branded ones, old drugs can be relaunched at astronomical prices, and low-cost options are shut out of the market. In Drugs, Money and Secret Handshakes, Robin Feldman shines a light into the dark corners of the pharmaceutical industry to expose a web of shadowy deals in which higher-priced drugs receive favorable treatment and patients are channeled toward the most expensive medicines. At the center of this web are the highly secretive middle players who establish coverage levels for patients and negotiate with drug companies. By offering lucrative payments to these middle players (as well as to doctors and hospitals), drug companies ensure that inexpensive drugs never gain traction. This system of perverse incentives has delivered the kind of exorbitant drug prices - and profits - that everyone loves except for those who pay the bills.

icer value assessment framework: International Handbook of Health Expectancies Carol Jagger, Eileen M. Crimmins, Yasuhiko Saito, Renata Tiene De Carvalho Yokota, Herman Van Oyen, Jean-Marie Robine, 2020-03-18 This handbook presents global research on health expectancies, a measure of population health that examines the interaction between quantity and quality of life. With data from Europe, North America, Asia, and beyond, it explains how to define and measure health and morbidity and how to integrate these measurements with mortality. Coverage first highlights long-term trends in longevity and health. It also considers variations across and within countries, inequalities, and social gaps as well as micro and macro-level determinants. Next, the handbook deals with the methodological aspects of calculating health expectancies. It compares results from different methods and introduces tools, such as decomposition tool for decomposing gaps, an attrition tool for attributing a medical cause to reported disability, and a tool for measuring policy impact on health expectancies. It introduces methods of forecasting health expectancies. The handbook then goes on to examine the synergies and/or trade-off between longevity and health as well as considers such topics as the compression versus the expansion of morbidity/disability and the health-survival paradox. The last section considers new concepts and dimensions of health and, more broadly, well being which can be used in summary measures of population health, including psychological factors. Researchers, clinicians, demographers, and health planners will find this handbook an essential resource to this increasingly important public health and social policy tool. It will help readers gain insight into changes in health over time as well as inequalities between countries, regions, and population subgroups.

icer value assessment framework: *Introduction to Market Access for Pharmaceuticals* Mondher Toumi, 2017-01-12 Market access is the fourth hurdle in the drug development process and the primary driver for global income of any new drug. Without a strategy in place for pricing, showing value for effectiveness and an understanding of the target purchasers' needs, the drug will fail to reach its intended market value. Introduction to Market Access for Pharmaceuticals is based on an accredited course in this area, taken from the European Market Access University Diploma (EMAUD), and is affiliated with Aix Marseille University. Key Features: The first guide to market access for pharmaceuticals based on tested teaching materials Addresses both pharmaceutical and vaccine products Includes case studies and scenarios Covers market access consdierations for Western Europe, the USA, Japan and China Explains the impact the changing healthcare market will have on your product

icer value assessment framework: Burger's Medicinal Chemistry, Drug Discovery and Development, 8 Volume Set , 2021-04-20 Burger's Medicinal Chemistry, Drug Discovery and Development Explore the freshly updated flagship reference for medicinal chemists and pharmaceutical professionals The newly revised eighth edition of the eight-volume Burger's Medicinal Chemistry, Drug Discovery and Development is the latest installment in this celebrated series covering the entirety of the drug development and discovery process. With the addition of expert editors in each subject area, this eight-volume set adds 35 chapters to the extensive existing chapters. New additions include analyses of opioid addiction treatments, antibody and gene therapy for cancer, blood-brain barrier, HIV treatments, and industrial-academic collaboration structures. Along with the incorporation of practical material on drug hunting, the set features sections on drug

discovery, drug development, cardiovascular diseases, metabolic diseases, immunology, cancer, anti-Infectives, and CNS disorders. The text continues the legacy of previous volumes in the series by providing recognized, renowned, authoritative, and comprehensive information in the area of drug discovery and development while adding cutting-edge new material on issues like the use of artificial intelligence in medicinal chemistry. Included: Volume 1: Methods in Drug Discovery, edited by Kent D. Stewart Volume 2: Discovering Lead Molecules, edited by Kent D. Stewart Volume 3: Drug Development, edited by Ramnarayan S. Randad and Michael Myers Volume 4: Cardiovascular, Endocrine, and Metabolic Diseases, edited by Scott D. Edmondson Volume 5: Pulmonary, Bone, Immunology, Vitamins, and Autocoid Therapeutic Agents, edited by Bryan H. Norman Volume 6: Cancer, edited by Barry Gold and Donna M. Huryn Volume 7: Anti-Infectives, edited by Roland E. Dolle Volume 8: CNS Disorders, edited by Richard A. Glennon Perfect for research departments in the pharmaceutical and biotechnology industries, Burger's Medicinal Chemistry, Drug Discovery and Development can be used by graduate students seeking a one-stop reference for drug development and discovery and deserves its place in the libraries of biomedical research institutes, medical, pharmaceutical, and veterinary schools.

icer value assessment framework: Gene and Cell Therapies Eve Hanna, Mondher Toumi, 2020-05-19 The major advances in the field of biotechnology and molecular biology in the twenty-first century have led to a better understanding of the pathophysiology of diseases. A new generation of biopharmaceuticals has emerged, including a wide and heterogeneous range of innovative cell and gene therapies. These therapies aim to prevent or treat chronic and serious life-threatening diseases, previously considered incurable. This book describes the evolution and adaptation of the regulatory environment to assess these therapies in contrast with the resistance of health technology assessment (HTA) agencies and payers to acknowledge the specificity of cell and gene therapies and the need to adapt existing decision-making frameworks. This book provides insights on the learnings from the experience of current cell and gene therapies (regulatory approval, HTA, and market access), in addition to future trends to enhance patient access to these therapies. Key Features: Describes the potential change of treatment paradigm and the specificity of cell and gene therapies, including the gradual move from repeated treatment administration to one-time single administration with the potential to be definite cure Highlights the challenges at the HTA level Discusses the affordability of future cell and gene therapies and the possible challenges for health insurance systems Provides potential solutions to address these challenges and ensure patient access to innovation while maintaining the sustainability of healthcare systems

icer value assessment framework: Market Access Management für Pharma- und Medizinprodukte Ralph Tunder, 2020-06-16 Die pharmazeutische Industrie steht im deutschen Gesundheitswesen häufig im Mittelpunkt kontroverser Kostendiskussionen. Als Resultat zielten die Maßnamen der Gesundheitspolitik in den letzten Jahren vorrangig auf (Kosten-)regulierungen der Arzneimittelindustrie ab, deren bisheriger Höhepunkt die Einführung des AMNOG im Jahr 2011 darstellte. Die bis dato freie Preisbildung wurde abgelöst durch ein zweistufiges Verfahren bestehend aus Nutzenbewertung und Preisverhandlung. Diese gravierenden Veränderungen der gesetzlichen Rahmenbedingungen für die Arzneimittelindustrie hatten einen erheblichen Bedeutungszuwachs des Themas Market Access zur Folge. Die Motivation zur Erstellung des Buches ist es, eine Publikation zu schaffen, die nicht nur den aktuellen Status widerspiegelt, sondern vielmehr auch die wesentlichen Instrumente und Verfahrensweisen aufzeigt und auch kritisch hinterfragt. Der Leser soll so einen Einblick in die Materie als auch nötiges Rüstzeug bei der konkreten Umsetzung erlangen. Das Buch dient dazu, Market Access Managern oder Interessierten fundiertes Hintergrundwissen zu vermitteln.

icer value assessment framework: Capitalizing a Cure Victor Roy, 2023-01-24 A free open access ebook is available upon publication. Learn more at www.luminosoa.org. Capitalizing a Cure takes readers into the struggle over a medical breakthrough to investigate the power of finance over business, biomedicine, and public health. When curative treatments for hepatitis C launched in 2013, sticker shock over their prices intensified the global debate over access to new medicines.

Weaving historical research with insights from political economy and science and technology studies, Victor Roy demystifies an oft-missed dynamic in this debate: the reach of financialized capitalism into how medicines are made, priced, and valued. Roy's account moves between public and private labs, Wall Street and corporate board rooms, and public health meetings and health centers to trace the ways in which curative medicines became financial assets dominated by strategies of speculation and extraction at the expense of access and care. Provocative and sobering, this book illuminates the harmful impact of allowing financial markets to determine who heals and who suffers and points to the necessary work of building more equitable futures.

icer value assessment framework: Hospital Management and Healthcare Policy: Financing, Resourcing and Accessibility Jay J. Shen, Hanadi Hamadi , Thomas T. H. Wan, Bing-Long Wang, 2024-07-31 Hospital management and healthcare policy are two related fields that significantly impact the delivery, accessibility, and quality of healthcare services. Hospital management refers to the administration and coordination of all the activities and resources in operating a hospital or healthcare facility, which includes strategic planning, financial management, human resources, patient care, and quality improvement. Effective hospital management is essential for ensuring the safety, quality of care, and cost-effective delivery of services. Healthcare policy refers to the regulations and guidelines that govern the provision and financing of healthcare services at the national, state, and local level. It encompasses issues such as healthcare access, affordability, quality, equity, effectiveness, and efficiency.

icer value assessment framework: *Real-World Evidence in Medical Product Development* Weili He, Yixin Fang, Hongwei Wang, 2023-05-11 This book provides state-of-art statistical methodologies, practical considerations from regulators and sponsors, logistics, and real use cases for practitioners for the uptake of RWE/D. Randomized clinical trials have been the gold standard for the evaluation of efficacy and safety of medical products. However, the cost, duration, practicality, and limited generalizability have incentivized many to look for alternative ways to optimize drug development. This book provides a comprehensive list of topics together to include all aspects with the uptake of RWE/D, including, but not limited to, applications in regulatory and non-regulatory settings, causal inference methodologies, organization and infrastructure considerations, logistic challenges, and practical use cases.

icer value assessment framework: *Personalised Health Care* Stefania Boccia, Róza Ádány, Paolo Villari, Martina C. Cornel, Corrado De Vito, Roberta Pastorino, 2020-11-23 Practitioners are increasingly adopting a personalised medicine approach to individually tailored patient care, especially disease diagnosis and treatment with the use of biomarkers. However, development and implementation of such approaches to chronic disease prevention need further investigation and concerted efforts for proper use in healthcare systems. This book provides high-quality, multidisciplinary knowledge from research in personalised medicine, specifically personalised prevention of chronic disease. It addresses different perspectives of prevention in the field, and is the outcome of a four-year work of the Personalized prevention of Chronic Disease (PRECeDI) Consortium, a multi-disciplinary and multi-professional team of experts. The Consortium jointly agreed to document and address the five aspects or domains of personalised medicine and prevention as individual chapters: Identification of biomarkers for the prevention of chronic disease Evaluation of predictive genomic applications Ethico-legal and policy issues surrounding personalised medicine Roles and responsibilities of stakeholders in informing healthy individuals on their genome: a sociotechnical analysis Identification of organisational models for the provision of predictive genomic applications The book focuses on the Consortium's recommendations that are derived from each of these domains based on up-to-date evidence and research that the authors write, follow, and systematically organise and report. Personalisation of health care is, eventually, a driver of innovation in research and healthcare systems. With this SpringerBrief on Personalised Health Care: Fostering Precision Medicine Advancements for Gaining Population Health Impact, the Consortium provides further evidence of the clinical validity and utility of personalised medicine with special emphasis on the prevention of chronic diseases. The book is a useful resource for policy

makers, industry and healthcare professionals, scientists, technology-sector professionals, investors, citizens, and private companies that need proper advice to realise the potential of personalised medicine.

icer value assessment framework: *Handbook of Applied Health Economics in Vaccines* William V. Padula, 2023 This book summarizes current theory and evidence relating to immunization supply, demand, distribution, and financing. It provides readers with an understanding of the obstacles faced in the field, and the possible approaches to corresponding solutions.

icer value assessment framework: Managing Biotechnology Francoise Simon, Glen Giovannetti, 2017-10-16 A comprehensive overview of the new business context for biopharma companies, featuring numerous case studies and state-of-the-art marketing models Biotechnology has developed into a key innovation driver especially in the field of human healthcare. But as the biopharma industry continues to grow and expand its reach, development costs are colliding with aging demographics and cost-containment policies of private and public payers. Concurrently, the development and increased affordability of sophisticated digital technologies has fundamentally altered many industries including healthcare. The arrival of new information technology (infotech) companies on the healthcare scene presents both opportunities and challenges for the biopharma business model. To capitalize on new digital technologies from R&D through commercialization requires industry leaders to adopt new business models, develop new digital and data capabilities, and partner with innovators and payers worldwide. Written by two experts, both of whom have had decades of experience in the field, this book provides a comprehensive overview of the new business context and marketing models for biotech companies. Informed by extensive input by senior biotech executives and leading consultancies serving the industry, it analyzes the strategies and key success factors for the financing, development, and commercialization of novel therapeutic products, including strategies for engagement with patients, physicians and healthcare payers. Throughout case studies provide researchers, corporate marketers, senior managers, consultants, financial analysts, and other professionals involved in the biotech sector with insights, ideas, and models. JACQUALYN FOUSE, PhD, RETIRED PRESIDENT AND CHIEF OPERATING OFFICER, CELGENE "Biotech companies have long been innovators, using the latest technologies to enable cutting edge science to help patients with serious diseases. This book is essential to help biotech firms understand how they can–and must–apply the newest technologies including disruptive ones, alongside science, to innovate and bring new value to the healthcare system." BRUCE DARROW, MD, PhD, CHIEF MEDICAL INFORMATION OFFICER, MOUNT SINAI HEALTH SYSTEM "Simon and Giovannetti have written an essential user's manual explaining the complicated interplay of the patients who deserve cutting-edge medical care, the biotechnology companies (big and small) creating the breakthroughs, and the healthcare organizations and clinicians who bridge those worlds." EMMANUEL BLIN, FORMER CHIEF STRATEGY OFFICER AND SENIOR VICE PRESIDENT, BRISTOL-MYERS SQUIBB "If you want to know where biopharma is going, read this book! Our industry is facing unprecedented opportunities driven by major scientific breakthroughs, while transforming itself to address accelerated landscape changes driven by digital revolutions and the emergence of value-based healthcare worldwide. In this ever-changing context, we all need to focus everything we do on the patients. They are why we exist as an industry, and this is ultimately what this insightful essay is really about." JOHN MARAGANORE, PRESIDENT AND CHIEF EXECUTIVE OFFICER, ALNYLAM PHARMACEUTICALS "Since the mapping of the human genome was completed nearly 15 years ago, the biotechnology industry has led the rapid translation of raw science to today's innovative medicines. However, the work does not stop in the lab. Delivering these novel medicines to patients is a complex and multifaceted process, which is elegantly described in this new book."

icer value assessment framework: *Regulatory and Economic Aspects in Oncology* Evelyn Walter, 2018-12-13 This book explores topics of importance to all who have an interest in economic methods for assessment of the efficacy and effectiveness of new cancer treatments and in regulatory measures relating to their marketing authorization and pricing. Targeted therapies and modern

immunotherapy are placing a substantial strain on health care budgets. Regulation and economic methods to assess the parameters for establishing efficacy and effectiveness are therefore of prime importance. Payer authorities have to determine whether the use of these novel therapies yields clinical benefits that justify their increasing cost. In the simplest terms, cost-effectiveness analyses quantify the ratio between the extent to which an intervention raises healthcare costs and the extent to which it improves health outcomes. Rigorous cost-effectiveness analyses translate all health outcomes into quality-adjusted life years. On the other hand, in order to sustain innovation, price regulations must be coupled with efforts to ensure that drug companies are still able to recoup their investments in high-risk and high-costs research programs. Ultimately, decisions regarding health care expenditures are also a question of society's willingness to pay.

Related to icer value assessment framework

ICER | Working Towards Fair Pricing, Fair Access, & Future Innovation 4 days ago ICER, in collaboration with researchers from Brown University, published a new white paper that provides clear policy and market solutions to help manage affordable and

About Us | Institute for Clinical & Economic Review - ICER The Institute for Clinical and Economic Review (ICER) is an independent, non-profit research institute that conducts evidence-based reviews of health care interventions, including

Explore Our Research | ICER ICER formally launched ICER Analytics™, a new cloud-based platform that will revolutionize the ability of payers, life science companies, patient groups, and others to

Assessments | Explore Our Research - ICER Find our most recent treatment assessments, or search from our archive of past assessments to find studies relating to treatments that matter to you

What is ICER | Institute for Clinical & Economic Review ICER provides an independent source of evidence review—free from financial conflicts of interest—to address these fundamental questions. Learn more

FAQs | What is ICER? | ICER ICER seeks to provide an independent source of evidence review—free from financial conflicts of interest—to help patients today and in the future by catalyzing a movement toward fair pricing,

Value Assessment Framework - ICER ICER's modified framework for ultra-rare conditions is the culmination of a nine-month public process of engagement with the rare disease patient community, the life sciences industry, and

Cost-Effectiveness, the QALY, and the evLY Gained - ICER As researchers that understand the appropriate and ethical use of cost-effectiveness, ICER has drafted a blueprint for policymakers seeking solutions on how to ensure proper use of the

News & Insights - ICER Learn about ICER's progress through our press releases, commentaries, and journal articles

Methods & Process | Our Approach - ICER ICER is driven by a mission to conduct evidence-based reviews of health care interventions, such as drug, devices and diagnostics, that help patients, doctors, and everyone else in the health

ICER | Working Towards Fair Pricing, Fair Access, & Future Innovation 4 days ago ICER, in collaboration with researchers from Brown University, published a new white paper that provides clear policy and market solutions to help manage affordable and

About Us | Institute for Clinical & Economic Review - ICER The Institute for Clinical and Economic Review (ICER) is an independent, non-profit research institute that conducts evidence-based reviews of health care interventions, including

Explore Our Research | ICER ICER formally launched ICER Analytics™, a new cloud-based platform that will revolutionize the ability of payers, life science companies, patient groups, and others to

Assessments | Explore Our Research - ICER Find our most recent treatment assessments, or search from our archive of past assessments to find studies relating to treatments that matter to you

What is ICER | Institute for Clinical & Economic Review ICER provides an independent source of evidence review—free from financial conflicts of interest—to address these fundamental questions. Learn more

FAQs | What is ICER? | ICER ICER seeks to provide an independent source of evidence review—free from financial conflicts of interest—to help patients today and in the future by catalyzing a movement toward fair pricing,

Value Assessment Framework - ICER ICER's modified framework for ultra-rare conditions is the culmination of a nine-month public process of engagement with the rare disease patient community, the life sciences industry,

Cost-Effectiveness, the QALY, and the evLY Gained - ICER As researchers that understand the appropriate and ethical use of cost-effectiveness, ICER has drafted a blueprint for policymakers seeking solutions on how to ensure proper use of the

News & Insights - ICER Learn about ICER's progress through our press releases, commentaries, and journal articles

Methods & Process | Our Approach - ICER ICER is driven by a mission to conduct evidence-based reviews of health care interventions, such as drug, devices and diagnostics, that help patients, doctors, and everyone else in the health

ICER | Working Towards Fair Pricing, Fair Access, & Future Innovation 4 days ago ICER, in collaboration with researchers from Brown University, published a new white paper that provides clear policy and market solutions to help manage affordable and

About Us | Institute for Clinical & Economic Review - ICER The Institute for Clinical and Economic Review (ICER) is an independent, non-profit research institute that conducts evidence-based reviews of health care interventions, including

Explore Our Research | ICER ICER formally launched ICER Analytics™, a new cloud-based platform that will revolutionize the ability of payers, life science companies, patient groups, and others to

Assessments | Explore Our Research - ICER Find our most recent treatment assessments, or search from our archive of past assessments to find studies relating to treatments that matter to you

What is ICER | Institute for Clinical & Economic Review ICER provides an independent source of evidence review—free from financial conflicts of interest—to address these fundamental questions. Learn more

FAQs | What is ICER? | ICER ICER seeks to provide an independent source of evidence review—free from financial conflicts of interest—to help patients today and in the future by catalyzing a movement toward fair pricing,

Value Assessment Framework - ICER ICER's modified framework for ultra-rare conditions is the culmination of a nine-month public process of engagement with the rare disease patient community, the life sciences industry, and

Cost-Effectiveness, the QALY, and the evLY Gained - ICER As researchers that understand the appropriate and ethical use of cost-effectiveness, ICER has drafted a blueprint for policymakers seeking solutions on how to ensure proper use of the

News & Insights - ICER Learn about ICER's progress through our press releases, commentaries, and journal articles

Methods & Process | Our Approach - ICER ICER is driven by a mission to conduct evidence-based reviews of health care interventions, such as drug, devices and diagnostics, that help patients, doctors, and everyone else in the health

ICER | Working Towards Fair Pricing, Fair Access, & Future Innovation 4 days ago ICER, in collaboration with researchers from Brown University, published a new white paper that provides clear policy and market solutions to help manage affordable and

About Us | Institute for Clinical & Economic Review - ICER The Institute for Clinical and Economic Review (ICER) is an independent, non-profit research institute that conducts evidence-based reviews of health care interventions, including

Explore Our Research | ICER ICER formally launched ICER Analytics™, a new cloud-based platform that will revolutionize the ability of payers, life science companies, patient groups, and others to

Assessments | Explore Our Research - ICER Find our most recent treatment assessments, or search from our archive of past assessments to find studies relating to treatments that matter to you

What is ICER | Institute for Clinical & Economic Review ICER provides an independent source of evidence review—free from financial conflicts of interest—to address these fundamental questions. Learn more

FAQs | What is ICER? | ICER ICER seeks to provide an independent source of evidence review—free from financial conflicts of interest—to help patients today and in the future by catalyzing a movement toward fair pricing,

Value Assessment Framework - ICER ICER's modified framework for ultra-rare conditions is the culmination of a nine-month public process of engagement with the rare disease patient community, the life sciences industry,

Cost-Effectiveness, the QALY, and the evLY Gained - ICER As researchers that understand the appropriate and ethical use of cost-effectiveness, ICER has drafted a blueprint for policymakers seeking solutions on how to ensure proper use of the

News & Insights - ICER Learn about ICER's progress through our press releases, commentaries, and journal articles

Methods & Process | Our Approach - ICER ICER is driven by a mission to conduct evidence-based reviews of health care interventions, such as drug, devices and diagnostics, that help patients, doctors, and everyone else in the health

ICER | Working Towards Fair Pricing, Fair Access, & Future Innovation 4 days ago ICER, in collaboration with researchers from Brown University, published a new white paper that provides clear policy and market solutions to help manage affordable and

About Us | Institute for Clinical & Economic Review - ICER The Institute for Clinical and Economic Review (ICER) is an independent, non-profit research institute that conducts evidence-based reviews of health care interventions, including

Explore Our Research | ICER ICER formally launched ICER Analytics™, a new cloud-based platform that will revolutionize the ability of payers, life science companies, patient groups, and others to

Assessments | Explore Our Research - ICER Find our most recent treatment assessments, or search from our archive of past assessments to find studies relating to treatments that matter to you

What is ICER | Institute for Clinical & Economic Review ICER provides an independent source of evidence review—free from financial conflicts of interest—to address these fundamental questions. Learn more

FAQs | What is ICER? | ICER ICER seeks to provide an independent source of evidence review—free from financial conflicts of interest—to help patients today and in the future by catalyzing a movement toward fair pricing,

Value Assessment Framework - ICER ICER's modified framework for ultra-rare conditions is the culmination of a nine-month public process of engagement with the rare disease patient community, the life sciences industry,

Cost-Effectiveness, the QALY, and the evLY Gained - ICER As researchers that understand the appropriate and ethical use of cost-effectiveness, ICER has drafted a blueprint for policymakers seeking solutions on how to ensure proper use of the

News & Insights - ICER Learn about ICER's progress through our press releases, commentaries, and journal articles

Methods & Process | Our Approach - ICER ICER is driven by a mission to conduct evidence-based reviews of health care interventions, such as drug, devices and diagnostics, that help patients, doctors, and everyone else in the health

ICER | Working Towards Fair Pricing, Fair Access, & Future Innovation 4 days ago ICER, in

collaboration with researchers from Brown University, published a new white paper that provides clear policy and market solutions to help manage affordable and

About Us | Institute for Clinical & Economic Review - ICER The Institute for Clinical and Economic Review (ICER) is an independent, non-profit research institute that conducts evidence-based reviews of health care interventions, including

Explore Our Research | ICER ICER formally launched ICER Analytics™, a new cloud-based platform that will revolutionize the ability of payers, life science companies, patient groups, and others to

Assessments | Explore Our Research - ICER Find our most recent treatment assessments, or search from our archive of past assessments to find studies relating to treatments that matter to you

What is ICER | Institute for Clinical & Economic Review ICER provides an independent source of evidence review—free from financial conflicts of interest—to address these fundamental questions. Learn more

FAQs | What is ICER? | ICER ICER seeks to provide an independent source of evidence review—free from financial conflicts of interest—to help patients today and in the future by catalyzing a movement toward fair pricing,

Value Assessment Framework - ICER ICER's modified framework for ultra-rare conditions is the culmination of a nine-month public process of engagement with the rare disease patient community, the life sciences industry, and

Cost-Effectiveness, the QALY, and the evLY Gained - ICER As researchers that understand the appropriate and ethical use of cost-effectiveness, ICER has drafted a blueprint for policymakers seeking solutions on how to ensure proper use of the

News & Insights - ICER Learn about ICER's progress through our press releases, commentaries, and journal articles

Methods & Process | Our Approach - ICER ICER is driven by a mission to conduct evidence-based reviews of health care interventions, such as drug, devices and diagnostics, that help patients, doctors, and everyone else in the health

Related to icer value assessment framework

Limitations of ICER's Value Assessment Framework Tool (The American Journal of Managed Care9y) Alan Balch, PhD: What ICER is trying to do is more like the Abacus. It is meant to be focused at policy makers and thought leaders, and to have a conversation about value-based pricing—as opposed to

Limitations of ICER's Value Assessment Framework Tool (The American Journal of Managed Care9y) Alan Balch, PhD: What ICER is trying to do is more like the Abacus. It is meant to be focused at policy makers and thought leaders, and to have a conversation about value-based pricing—as opposed to

ICER and Aetion partner to develop real-world evidence for value assessment of treatments (Business Insider5y) NEW YORK, Feb. 24, 2020 /PRNewswire/ -- Today, the Institute for Clinical and Economic Review (ICER) announced it has selected Aetion as a preferred partner and platform to generate decision-grade

ICER and Aetion partner to develop real-world evidence for value assessment of treatments (Business Insider5y) NEW YORK, Feb. 24, 2020 /PRNewswire/ -- Today, the Institute for Clinical and Economic Review (ICER) announced it has selected Aetion as a preferred partner and platform to generate decision-grade

Alliance for Aging Research Submits Comment to ICER on Alzheimer's Disease Value Assessments (Insurancenewsnet.com4y) To accurately assess the value of Alzheimer's disease treatments, Milliman's report outlines an alternative, equitable value assessment framework for use in AD that accounts for the ecosystem that

Alliance for Aging Research Submits Comment to ICER on Alzheimer's Disease Value Assessments (Insurancenewsnet.com4y) To accurately assess the value of Alzheimer's disease

treatments, Milliman's report outlines an alternative, equitable value assessment framework for use in AD that accounts for the ecosystem that

Report suggests new framework to assess value of Alzheimer's therapies (McKnight's Long-Term Care News4y) The Institute for Clinical and Economic Review's traditional value assessment methodologies for complex conditions such as Alzheimer's disease fail to address the full burden on patients, caregivers

Report suggests new framework to assess value of Alzheimer's therapies (McKnight's Long-Term Care News4y) The Institute for Clinical and Economic Review's traditional value assessment methodologies for complex conditions such as Alzheimer's disease fail to address the full burden on patients, caregivers

The Complicated Dynamics of Insurance Companies and Drug Prices (Washington Examiner9y) What constitutes a "fair" price for a drug? Unsurprisingly, that depends on who's asking the question, as well as who's answering. To get a price that can actually be construed as fair, it is

The Complicated Dynamics of Insurance Companies and Drug Prices (Washington Examiner9y) What constitutes a "fair" price for a drug? Unsurprisingly, that depends on who's asking the question, as well as who's answering. To get a price that can actually be construed as fair, it is

Value Assessment's "Leaky Bucket" Problem Needs To Be Addressed (Health Affairs3y) Recent scientific developments in medicine have the potential to cure or fundamentally modify previously incurable or poorly treated diseases and conditions, relieving the suffering of patients and

Value Assessment's "Leaky Bucket" Problem Needs To Be Addressed (Health Affairs3y) Recent scientific developments in medicine have the potential to cure or fundamentally modify previously incurable or poorly treated diseases and conditions, relieving the suffering of patients and

Back to Home: https://admin.nordenson.com